Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis

Kreuzberger, Nina; Damen, Johanna Aag; Trivella, Marialena; Estcourt, Lise J; Aldin, Angela; Umlauff, Lisa; Vazquez-Montes, M; Wolff, Robert; Moons, Karel G.M.; Monsef, Ina; Foroutan, Farid; Kreuzer, Karl‐Anton; Skoetz, Nicole

doi:10.1002/14651858.cd012022.pub2

Cited by 31 publications

(33 citation statements)

References 300 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 We are aware, however, that the model may integrate but not replace clinical expertise and medical judgment. 6,7…”

Section: Prognostic Models In Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib Therapy: Results Of a Comparative Performance Anamentioning

confidence: 99%

Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis

Molica

Baumann²,

Giannarelli

2020

European J of Haematology

View full text Add to dashboard Cite

“…5 We are aware, however, that the model may integrate but not replace clinical expertise and medical judgment. 6,7…”

Section: Prognostic Models In Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib Therapy: Results Of a Comparative Performance Anamentioning

confidence: 99%

Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis

Molica

Baumann²,

Giannarelli

2020

European J of Haematology

View full text Add to dashboard Cite

“…Several prognostic algorithms derived from multivariable models, nomograms and score systems have been developed to predict clinical outcomes accurately in early-stage CLL ( 64 ). The IGHV gene configuration is one of the most important single factors predicting therapy need, and it is recurrently incorporated in all prognostic models ( 65 ).…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

et al. 2021

View full text Add to dashboard Cite

The prognostic role of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was recognized more than three decades ago when the neoplastic clone’s biology was almost unknown. LDT was defined as the time needed for the peripheral blood lymphocyte count to double the of the initial observed value. Herein, the LDT prognostic value for time to first treatment (TTFT) was explored in our prospective O-CLL cohort and validated in in two additional CLL cohorts. Specifically, newly diagnosed Binet stage A CLL patients from 40 Italian Institutions, representative of the whole country, were prospectively enrolled into the O-CLL1-GISL protocol (clinicaltrial.gov identifier: NCT00917540). Two independent cohorts of newly diagnosed CLL patients recruited respectively at the Division of Hematology in Novara, Italy, and at the Hospital Clinic in Barcelona, Spain, were utilized as validation cohorts. In the training cohort, TTFT of patients with LDT >12 months was significantly longer related to those with a shorter LDT. At Cox multivariate regression model, LDT ≤ 12 months maintained a significant independent relationship with shorter TTFT along with IGHV unmutated (IGHVunmut) status, 11q and 17p deletions, elevated β2M, Rai stage I-II, and NOTCH1 mutations. Based on these statistics, two regression models were constructed including the same prognostic factors with or without the LDT. The model with the LTD provided a significantly better data fitting (χ2 = 8.25, P=0.0041). The risk prediction developed including LDT had better prognostic accuracy than those without LDT. Moreover, the Harrell’C index for the scores including LDT were higher than those without LDT, although the accepted 0.70 threshold exceeded in both cases. These findings were also confirmed when the same analysis was carried out according to TTFT’s explained variation. When data were further analyzed based on the combination between LDT and IGHV mutational status in the training and validation cohorts, IGHVunmut and LDT>12months group showed a predominant prognostic role over IGHVmut LTD ≤ 12 months (P=0.006) in the O-CLL validation cohort. However, this predominance was of borden-line significance (P=0.06) in the Barcelona group, while the significant prognostic impact was definitely lost in the Novara group. Overall, in this study, we demonstrated that LDT could be re-utilized together with the more sophisticated prognostic factors to manage the follow-up plans for Binet stage A CLL patients.

show abstract

“…It consists of four domains: participants, predictors, outcome, and analysis, and includes twenty specific items facilitating quality control (157). The assessment tool was designed for the systematic review of prediction model studies and has been applied in many areas including breast cancer, kidney cancer, lymphocytic leukaemia, and oropharyngeal cancer (158)(159)(160)(161). We assessed the bias of the nine studies mentioned above using PROBAST and the results are shown in Table 2.…”

Section: Bias Assessment Based On Probastmentioning

confidence: 99%

A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models?

2021

View full text Add to dashboard Cite

Objective: To discover potential predictors and explore how to build better models by summarizing the existing prognostic prediction models of non-small cell lung cancer (NSCLC).Background: Research on clinical prediction models of NSCLC has experienced explosive growth in recent years. As more predictors of prognosis are discovered, the choice of predictors to build models is particularly important, and in the background of more applications of next-generation sequencing technology, gene-related predictors are widely used. As it is more convenient to obtain samples and followup data, the prognostic model is preferred by researchers.Methods: PubMed and the Cochrane Library were searched using the items "NSCLC", "prognostic model", "prognosis prediction", and "survival prediction" from 1 January 1980 to 5 May 2021. Reference lists from articles were reviewed and relevant articles were identified. Conclusions:The performance of gene-related models has not obviously improved. Relative to the innovation and diversity of predictors, it is more important to establish a highly stable model that is convenient for clinical application. Most of the prevalent models are highly biased and referring to PROBAST at the beginning of the study may be able to significantly control the bias. Existing models should be validated in a large external dataset to make a meaningful comparison.

show abstract

Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis

Abstract: Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Cited by 31 publications

References 300 publications

Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis

Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models?

Contact Info

Product

Resources

About